Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ

JAMA

Volumn 293, Issue 8, 2005, Pages 964-969

  Claus, Elizabeth B ^a,c   Petruzella, Stacey ^a   Matloff, Ellen ^b   Carter, Darryl ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN;

ADULT; AGED; ARTICLE; CARCINOMA IN SITU; CASE CONTROL STUDY; CLINICAL PROTOCOL; CONTROLLED STUDY; ETHNOLOGY; FAMILY HISTORY; FEMALE; GENE MUTATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; BREAST TUMOR; GENETICS; MIDDLE AGED; MUTATION; PAGET NIPPLE DISEASE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MUTATION;

EID: 13944260510     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.8.964     Document Type: Article

References (51)

1. Malone KE, Daling JR, Thompson JD, O'brien CA, Francisco LV, Ostrander EA. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 1998;279:922-929.
2. Newman B, Mu H, Butler LM, Millikan RC, Moorman PC, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998;279:915-921.
3. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91:943-949.
4. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer. 2000;36:1200-1208.
5. De Sanjose S, Leone M, Berez V, et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer. 2003;106:588-593.
6. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000;92:1529-1531.
7. Loman N, Johannsson O, Kristofferson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst. 2001;93:1215-1223.
8. Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996;334:137-142.
9. Fitzgerald MG, MacDonald DJ, Krainer M, et al. Germ-line mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996;334:143-149.
10. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-646.
11. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. JAMA. 1997;278:1242-1250.
12. Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenaki Jewish women affected by breast cancer. Nat Genet. 1996;13:126-128.
13. Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996;347:1643-1645.
14. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAC mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995;11:198-200.
15. Martin AM, Blackwood MA, Antin-Ozerkis D, et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001;19:2247-2253.
16. Couch FJ, DeShano ML, Blackwood A, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409-1415.
17. Krainer M, Silva-Arrieta S, Fitzgerald MG, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med. 1997;336:1416-1421.
18. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 1996;56:3663-3665.
19. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60:1079-1084.
20. Sun CC, Lenoir C, Lynch H, Narod S. In-situ breast cancer and BRCA1. Lancet. 1996;348:408.
21. Jacquemier J, Eisinger F, Guinebretiere JM, Stoppa-Lyonnet D, Sobol H. Intraductal component and BRCA1-associated breast cancer. Lancet. 1996;348:1098.
22. Armes JE, Egan AJM, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before 40 years in women with and without BRCA1 or BRCA2 mutations. Cancer. 1998;83:2335-2345.
23. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology. 2002;34:309-314.
24. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol. 2003;21:41-45.
25. Adem C, Reynolds C, Soderberg CL, et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutations carriers. Cancer. 2003;97:1-11.
26. Claus EB, Stowe M, Carter D. Breast carcinoma in-situ: risk factors and screening patterns. J Natl Cancer Inst. 2001;93:1811-1817.
27. Claus EB, Stowe M, Carter D. Oral contraceptive use and the risk of ductal breast carcinoma in-situ. Breast Cancer Res Treat. 2003;81:129-136.
28. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in-situ. Breast Cancer Res Treat. 2003;78:7-15.
29. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16:2417-2425.
30. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480-1490.
31. Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and a family history of breast cancer. Cancer. 1993;71:147-153.
32. Claus EB, Stowe M, Carter D. The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast. 2003;12:451-456.
33. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349:1505-1510.
34. Caldes T, de la Hoya M, Tosar A, et al. A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes. J Med Genet. 2002;39:E44.
35. Stoppa-Lyonnet D, Fricker JP, Essioux L, et al. Segregation of two BRCA1 mutations in a single family. Am J Hum Genet. 1996;59:479-481.
36. Randall TC, Bell KA, Rebase BA, Rubin SC, Boyd J. Germline mutations of the BKCA1 and BKCA2 genes in a breast and ovarian cancer patient. Gynecol Oncol. 1998;70:432-434.
37. Loader S, Rowley PT. Deleterious mutations of both BRCA1 and BRCA2 in three siblings. Genet Test. 1998;2:75-77.
38. Ganguly A, Citron M, Godmilow L, Ahrens M, Ganguly T. Caucasian family with two independent mutations: 2594delC in BRCA1 and 5392delAG in BRCA2 gene. Am J Med Genet. 2001;101:146-152.
39. Ramus SJ, Friedman LS, Gayther SA, et al. A breast/ovarian patient with germline mutations in both BRCA1 and BRCA2. Nat Genet. 1997;15:14-15.
40. Tesoriero A, Anderson C, Southey M, et al. De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet. 1999;65:567-569.
41. Friedman E, Bar-Sade Bruchim R, Kruglikova A, et al. Double herterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet. 1998;63:1224-1227.
42. Tsongalis GJ, Linfert DR, Johnson RC, et al. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Arch Pathol Lab Med. 1998;122:548-550.
43. Liede A, Rehal P, Vesprini D, Jack E, Abrahamson J, Narod SA. A breast cancer patient of Scottish descent with germline mutations in BRCA1 and BRCA2. Am J Hum Genet. 1998;62:1543-1544.
44. Gershoni-Baruch R, Dagan E, Kepten I, Fried G. Co-segregation of BRCA1 185delAG mutation and BRCA2 6174delT in one family. Eur J Cancer. 1997;33:2283-2284.
45. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57:1457-1462.
46. Unger MA, Nathanson KL, Calzone K, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis. Am J Hum Genet. 2000;67:841-850.
47. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
48. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
49. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet. 1994;343:692-695.
50. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998;351:316-321.
51. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53:141-169.